Skip to main content
Fig. 5 | BMC Complementary Medicine and Therapies

Fig. 5

From: Identification and validation of targets of swertiamarin on idiopathic pulmonary fibrosis through bioinformatics and molecular docking-based approach

Fig. 5

The expressions (A) and the statistics results (B) of COL5A2, LOX, and CTGF in the western blot analysis. *Represents the P < 0.05. The A549 cells (control group) were pretreated with 10ng/ml of TGF-β1 to build the in vitro IPF model, and then the cells were treated with 1.5µmol/l of swertiamarin (test group) for 24 h. The samples for determining the expressions of COL5A2, LOX, CTGF, and GAPDH (glyceraldehyde 3-phosphate dehydrogenase) were derived from the same batch of experiments. The gels were processed in parallel

Back to article page

BMC Complementary Medicine and Therapies

ISSN: 2662-7671

Contact us